No Result
View All Result
  • Home
  • Market Sectors
    • Technology
    • Health
    • Finance
    • Consumer
    • Commercial Services
    • Electronic
    • Communications
    • Transportation
    • Utilities
    • Minerals
    • Other Sectors
    • Electric Vehicles
    • Pot Stock
    • 5G Stock
    • Crypto
  • Stock Analyst News
  • Earnings News
  • Insider Trades
  • Dividend Stocks
Subscribe Now
  • Home
  • Market Sectors
    • Technology
    • Health
    • Finance
    • Consumer
    • Commercial Services
    • Electronic
    • Communications
    • Transportation
    • Utilities
    • Minerals
    • Other Sectors
    • Electric Vehicles
    • Pot Stock
    • 5G Stock
    • Crypto
  • Stock Buys
    • Strong Buys
    • Insider Buys
  • Insider Trades
  • Dividend Stocks
  • Event Calendars
    • Earnings and Dividend
    • IPO
  • Special Reports
No Result
View All Result
HOME MARKET SECTORS STOCK BUYS INSIDER TRADES DIVIDEND STOCKS
     BACK TO MENU Technology Health Finance Consumer Commercial Services Electronic Communications Transportation Utilities Minerals Other Sectors Electric Vehicles Pot Stock 5G Stock Crypto
politicsandwallstreet.com
No Result
View All Result

BioMarin Pharmaceutical Trending

by Staff Editor
Jun 03, 2022
in Health Watchlist healthcare stocks 

Powered by HealthTechMovers.com

According to healthtechmovers.com, there is a a list of several health stocks that have appear to be trending by receiving buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding them to our watchlist.

 BioMarin Pharmaceutical, BMRN
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
Geoff Meacham analyst at Bank of America Securities reiterates coverage on BioMarin Pharmaceutical (BMRN) in the health sector with a Buy rating and has set a price target of $ 120.

TipRanks.com reports that BioMarin Pharmaceutical currently has 15 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target of $113.67. 

In addition, TradingView issued a Sell rating for BMRN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN.

For the complete breakdown on BMRN, please click here >>

PoliticsAndWallStreet.com

One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals.  TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>

PoliticsAndWallStreet.com

Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.    
==============================================================================
Tags: healthcare stocks healthcare stock movers Healthcare stock watchlist health stocks BioMarin Pharmaceutical stock 

Related Posts

From Shrinkflation to Economic Collapse: Is a Financial Storm Brewing?

Oct 13, 2024

The Week Ahead: Earnings Season Kicks Off and Retail Sales in Focus

Oct 13, 2024
Dividend 

4 Stocks Up 30%+ in 5 Days: EV, Lithium, and Tech Leaders

Oct 09, 2024
UP Fintech Holding Limited stock TIGR TIGR price target Financial Services stock watchlist Financial Services stocks 

4 Soaring Stocks Up Over 46% in 5 Days

Oct 04, 2024
Dividend 

3 Dividend Stocks Up Over 30% in the Last Week

Oct 04, 2024

Massive "Backdoor" Pre-IPO Play in Musk's $100 Billion Starlink?

Oct 03, 2024
Next Post
Canadian regulator rejects Enbridge plan to contract oil pipeline space

Canadian regulator rejects Enbridge plan to contract oil pipeline space

Nvidia’s DLSS has come to Linux gaming (but not the Steam Deck obviously)

Nvidia’s DLSS has come to Linux gaming (but not the Steam Deck obviously)

No Result
View All Result

Screener data might be 15 minutes delayed from the real time.

  • Newsletters
  • Advertise with Us
  • About Us
  • Feedback/Contact Us
  • Email Notice, Data Use and DMCA
  • Privacy Policy
  • Terms of Use and Disclaimer
  • 17B List of Disclosures
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This site contains articles and videos are offered for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation or be relied upon as personalized investment advice. We are a financial publisher. We are not financial advisors and cannot give personalized advice. There is a risk of loss in all trading, and you may lose some or all of your original investment. Results presented are not typical. Never make any investment or trade with our first consulting with your investment advisor and after doing your own due diligence. This webpage and website is protected by copyright laws of the United states and international treaties.

©2021 Sandpiper Marketing Group
PO Box 407. Mt. Mourne, NC 28123-0407

  • Home
  • Market Sectors
    • Technology
    • Health
    • Finance
    • Consumer
    • Commercial Services
    • Electronic
    • Communications
    • Transportation
    • Utilities
    • Minerals
    • Other Sectors
    • Electric Vehicles
    • Pot Stock
    • 5G Stock
    • Crypto
  • Stock Buys
    • Strong Buys
    • Insider Buys
  • Insider Trades
  • Dividend Stocks
  • Event Calendars
    • Earnings and Dividend
    • IPO
  • Special Reports

©2021 Sandpiper Marketing Group

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In